Monday, December 18, 2023 10:10:42 AM
manibiotech,
It’s worse than that for you all because you can’t come up with a single CDMO that went on to produce a game changing platform technology capable of treating all solid tumor cancers. An example like that would form some sort of defense for your assertion that NWBO should have taken on the full burden of CDMO development while spending on research and development of their initially unproven and widely unsupported platform technology but you have no example. There are plenty of examples of failed trials by big pharma and failed biotechs because the did not have the wear withal to recover from trial failure or from over extending their resources.
While you all conger up recipes for disaster and pretend they are recipes for success NWBO moves ahead, leading the pack while chronicling the pathway to real success and benefit for cancer patients.
While you attempt to create dissensions by appealing to self centered short sightedness you also ignore the fact that somehow this board’s success at calling the shots with regard to validation of the science and upward price trend from the double bottom in March 2020 until now should be disregarded. Only those unwilling to do the least bit of due diligence would possibly fall for what you are saying. The rest of us watch those howling at the moon with their swan song; ). Best wishes.
It’s worse than that for you all because you can’t come up with a single CDMO that went on to produce a game changing platform technology capable of treating all solid tumor cancers. An example like that would form some sort of defense for your assertion that NWBO should have taken on the full burden of CDMO development while spending on research and development of their initially unproven and widely unsupported platform technology but you have no example. There are plenty of examples of failed trials by big pharma and failed biotechs because the did not have the wear withal to recover from trial failure or from over extending their resources.
While you all conger up recipes for disaster and pretend they are recipes for success NWBO moves ahead, leading the pack while chronicling the pathway to real success and benefit for cancer patients.
While you attempt to create dissensions by appealing to self centered short sightedness you also ignore the fact that somehow this board’s success at calling the shots with regard to validation of the science and upward price trend from the double bottom in March 2020 until now should be disregarded. Only those unwilling to do the least bit of due diligence would possibly fall for what you are saying. The rest of us watch those howling at the moon with their swan song; ). Best wishes.
Recent NWBO News
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
